1. Brown, J. M. and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408–1416, 1998
2. Gatenby, R. A. and Maini, P. M. Mathematical oncology. Nature, 421: 321, 2003
3. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. Molecular Biology of the Cell (3rd ed.), p. 1267. New York, NY: Garland Publishing, Inc., 1994.
4. Gatenby, R. A. and Gawlinski, E. T. A reaction-diffusion model of cancer invasion. Cancer Res., 56: 4740–4743, 1996.
5. Gatenby, R. A. Population ecology issues in tumor growth. Cancer Res., 51: 2541–2547, 1991.
6. Adam, J. A. and Bellomo, N. (eds.). A Survey of Models for Tumour-Immune System Dynamics. Boston, MA: Birkhauser, 1996.
7. Murray, J. D. Mathematical Biology (2nd ed.), pp. 80–81. Berlin: Springer, 1993.
8. Volterra, V. Variazionie fluttuazioni del numero d'individvi in specie animali conviventi. Mem. Acad. Lincei, 2: 21–113, 1926.
9. Lotka, A. J. Undamped oscillations derived from the law of mass action. J. Am. Chem. Soc., 42: 1595–1599, 1920
10. Fearon, E. R. and Vogelstein, B. A. A genetic model for colorectal tumorigenesis. Cell, 61: 759–767, 1991.
11. Ilyas, M., Straub, J., Tomlinson, I. P. M., and Bdmer, W. F. Genetic pathways in colorectal and other cancers. Eur. J. Cancer, 35: 335–351, 1999.
12. Yasuda, S., Fujii, H., Nakahara, Y., Nishiumi, M., Takahashi, W., Ide, M., and Shohtsu, A. 18f-FDG PET detection of colonic adenomas. J. Nucl. Med., 42: 989–992, 2001
13. Park, H. J., Lyons, J. C., Ohtsubo, T., and Song, C. W. Acidic environment causes apoptosis by increasing caspase activity. Br. J. Cancer, 80: 1892–1897, 1999
14. Williams, A. C., Collard, T. J., and Paraskeva, C. An acidic environment leads to p53 dependent induction of apoptosis. Oncogene, 18: 3199–3204, 1999
15. Rohzin, J., Sameni, M., Ziegler, G., and Sloane, B. F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res., 54: 6517–6525, 1994
16. Lardner, A. The effects of extracellular pH on immune function. Leuk. Biol., 69: 522–530, 2001.
17. Xu, L. and Fidler, I. J. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res., 60: 4610–4616, 2000
18. Shi, Q., Le, X., Wang, B., Abbruzzese, J. L., Xiong, Q., He, Y., and Xie, K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene, 20: 3751–3756, 2001
19. von Mehren, M., Adams, G. P., and Weiner, L. M. Monoclonal antibody therapy for cancer. Annu. Rev. Med., 54: 334–369, 2003.
20. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegelll, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet, 343: 1177–1183, 1994
21. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hofken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788–1794, 1998
22. Fan, Z., Baslega, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637–4642, 1992.
23. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327–1333, 1993
24. Coldman, A. J. and Goldie, J. H. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math. Biosci., 65: 292–307, 1983.
25. Vincent, T. L., Cohen, Y., and Brown, J. S. Evolution via strategy dynamics. Theor. Popul. Biol., 44: 149–176, 1993
26. Vincent, T. L. Strategy dynamics and the ESS. In: Dynamics of Complex Interconnected Biological Systems, Mathematical Modeling, pp. 236–249. Boston, MA: Birkhäuser, 1990.
27. Vincent, T. L. and Brown, J. S. An evolutionary response to harvesting. In: Modeling and Management of Resources under Uncertainty, Lecture Notes in Biomathematics, pp. 83–99. Heidelberg: Springer-Verlag, 1987.
28. Case, T. J. Coevolution in resource-limited competition communities. Theor. Popul. Biol., 21: 69–91, 1982.
29. Rummel, J. D. and Roughgarden, J. Some differences between invasion-structured and coevolution structured competitive communities: a preliminary theoretical analysis. Oikos, 41: 477–486, 1983.
30. Rummel, J. D. and Roughgarden, J. A theory of faunal buildup for competition communities. Evolution, 39: 1009–1033, 1985
31. Brown, J. S. and Vincent, T. L. Coevolution as an evolutionary game. Evolution, 41: 66–79, 1987
32. Hines, W. G. S. Evolutionary stable strategies: a review of basic theory. Theor. Popul. Biol., 31: 195–272, 1987
33. Vincent, T. L. and Brown, J. S. Stability in an evolutionary game. Theor. Popul. Biol., 26: 408–427, 1984
34. Vincent, T. L. An evolutionary game theory for differential equation models with reference to ecosystem management. In: T. Basar and A. Haurie (eds.), Advances in Dynamic Games and Applications, pp. 356–374. Boston, MA: Birkhauser, 1994.
35. Ichihashi, M. and Kitajima, Y. Chemotherapy induces or increases expression of multi-drug resistance-associated protein in malignant melanoma cells. Br. J. Dermatol., 144: 745–750, 2001
36. Matsumoto, Y., Takano, H., and Fojo, T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res., 57: 5086–5092, 1997
37. Ciardiello, F., Bianco, R., Damiano, V., De Lorennnzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5: 509–516, 1999.
38. Petit, A., Rak, J., Hung, M., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implication for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523–1530, 1997
39. Cobleigh, M., Vogel, C., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-ovrexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639–2648, 1999
40. Slamon, D., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic disease that overexpresses HER2. N. Engl. J. Med., 344: 783–792, 2001
41. Norton, L., Slamon, D., and Leyland-Jones, B. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anit-HER2 monoclonal antibody Herceptin (H) in HER2-over-expressing (HER2+) metastatic breast cancer (MBC) (Abstract). Proc. Am. Soc. Clin. Oncol., 18: A127, 1999.
42. Baselga, J. Clinical trials of Herceptin (trastuzuman). Eur. J. Cancer, 37: S18–S24, 2001.
Answers to all your Biology Questions
